Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Poorva Vaidya
Institutions:
University of California, Irvine,
UC Irvine Chao Family Comprehensive Cancer Center
Observed institutions:
University of Southern California,
University of California, Los Angeles,
University of California, Irvine,
Keck Hospital of USC,
University of California San Diego,
UC Irvine Health,
Moores Cancer Center,
UC Irvine Chao Family Comprehensive Cancer Center
show all 8
ORCID:
0000-0002-5506-4250
Observed ORCID:
0000-0002-5506-4250
OpenAlex ID:
A5090788292
IL-32 is a molecular marker of a host defense network in human tuberculosis
2014
·
Dennis Montoya
, Megan S. Inkeles
, et al.
·
Science Translational Medicine
·
134
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California
2020
·
Gino K. In
, Poorva Vaidya
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
32
Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma
2019
·
Poorva Vaidya
, Arjun Mehta
, et al.
·
JAAD Case Reports
·
21
PDF
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
2023
·
Poorva Vaidya
, Ezra E.W. Cohen
·
Clinical Cancer Research
·
16
PDF
Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic
2020
·
Zaki Hasnain
, Tanachat Nilanon
, et al.
·
JCO Clinical Cancer Informatics
·
8
Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma
2025
·
Poorva Vaidya
, Sharon Wu
, et al.
·
Cancers
·
6
PDF
Midostaurin-Related Interstitial Lung Injury in FLT3+ Acute Myeloid Leukemia Post-Allogeneic Transplant
2019
·
Poorva Vaidya
, Tarek Khedro
, et al.
·
World Journal of Oncology
·
6
PDF
IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine
2023
·
Poorva Vaidya
, Huan-You Wang
, et al.
·
Leukemia Research Reports
·
3
Bone Marrow Features in Patients With Acute Myeloid Leukemia Treated With Novel Targeted Isocitrate Dehydrogenase 1/2 Inhibitors
2019
·
Ashley Hagiya
, Poorva Vaidya
, et al.
·
World Journal of Oncology
·
3
PDF
420 Baseline cortisol levels in patient receiving immune checkpoint inhibition for advanced melanoma
2026
·
Hee Kyung Kim
, Kylie Cox
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
2026
·
Clara J Oh
, Jingshu Chen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Induction Systemic Therapy Followed by Response-Adapted Consolidative Radiation in Locally Advanced Non-Melanoma Skin Cancer: A Retrospective Case Series
2026
·
Poorva Vaidya
, Tali Azenkot
, et al.
·
Current Oncology
Phase 2 study of metronomic cyclophosphamide with pembrolizumab in checkpoint inhibitor–refractory melanoma.
2026
·
Poorva Vaidya
, Warren Allen Chow
·
Journal of Clinical Oncology
PDF
604 Phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma
2025
·
Soo Park
, Omid Najmi
, et al.
·
Journal of Clinical Oncology
PDF
Secondary Malignancy in Kidney Transplant Recipients: University of Southern California Experience
2020
·
Alexandra K. Wong
, Tiffany Truong
, et al.
·
Journal of the American Society of Nephrology
Show more works
View as search
Works count:
15
Citation count:
229
H-index:
6
I10-index:
4
Year
Topic
Type